Please type a plus sign (+) inside this box

1

19991924 TOS

PTO/8B/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

C mplete if Known Substitute for form 1449A/PTO **Application Number** 09/919,224 INFORMATION DISCLOSURE July 30, 2001 Filing Date STATEMENT BY APPLICANT **First Named Inventor** Schall, Thomas J. Unassigned Group Art Unit (use as many sheets as necessary) **Examiner Name** Unassigned 019934-001710US Sheet Attorney Docket Number

	Examiner Initials *	Cite No.1	U.S. Patent Document				Pages, Columns, Lines,
			Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear
0 4			-				
	20 80 (2)				BESTAV	MINDLE	'OPY
2 6	2002 66 RIV OTTO						
							· · · · · · · · · · · · · · · · · · ·
ADEM	HI.						
			 				
			 		<u> </u>		

Examiner Initials*	Cite No.1	Foreign Patent Document			N PATENT DOCU	Date of Publication of	Pages, Columns, Lines, Where Relevant	
		Office ³	Number ⁴	Kind Code ⁵ (<i>if known</i>)	or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	T ⁶
MB	1	wo	01/16153	A1	University of Medicine and Dentistry of New Jersey	03-08-2001		
	-							
		 	 					

Examiner Signature	Date Considered	7/7/03
		ι

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



of

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

019934-001710US

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number

[99/919,224

Filing Date

July 30, 2001

First Named Inventor

Group Art Unit

Unassigned

Examiner Name

Unassigned

Attorney Docket Number

m 8		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Caminer Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	т
MB	2	ESSA et al., Th1-Type Cytokines Production Is Decreased in Kidney Transplant Recipients With Active Cytomegalovirus Infection, J. Med. Virol. February 2000, Vol. 60, pages 223-229.	
	3	KOTENKO et al., Human Cytomegalovirus Harbors Its Own Unique IL-10 Homolog(cmvIL-10), Proc. Natl. Acad. Sci. USA. February 2000, Vol. 97, pages 1695-1700.	
	4	LOCKRIDGE et al., Primate Cytomegalovirus Encode and Express an IL-10-like Protein. Virology, March 2000, Vol. 268, pages 272-280.	
MUS	5	NORDOY et al., The Role of the Tumor Necrosis Factor System and Interleukin-10 During Cytomegalovirus Infection in Renal Transplant Recipients. J. Infect. Dis. January 2000, Vol. 181, pages 51-57.	
		BEST AVAILABLE COPY	
			<u> </u>
			_
		·	<u> </u>
		·	

Examiner Signature	7095	<u>Date</u> Considered	7/7/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. PA 3199812 v1



¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.